Loxo Oncol Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LOXO ONCOL
LOXO ONCOL has one approved drug.
There are seven US patents protecting LOXO ONCOL drugs.
Summary for Loxo Oncol
| US Patents: | 7 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Loxo Oncol
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Loxo Oncol | JAYPIRCA | pirtobrutinib | TABLET;ORAL | 216059-001 | Jan 27, 2023 | RX | Yes | No | 10,695,323 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Loxo Oncol | JAYPIRCA | pirtobrutinib | TABLET;ORAL | 216059-001 | Jan 27, 2023 | RX | Yes | No | 12,268,666 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Loxo Oncol | JAYPIRCA | pirtobrutinib | TABLET;ORAL | 216059-001 | Jan 27, 2023 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Loxo Oncol | JAYPIRCA | pirtobrutinib | TABLET;ORAL | 216059-002 | Jan 27, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Loxo Oncol | JAYPIRCA | pirtobrutinib | TABLET;ORAL | 216059-002 | Jan 27, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Loxo Oncol | JAYPIRCA | pirtobrutinib | TABLET;ORAL | 216059-002 | Jan 27, 2023 | RX | Yes | Yes | 10,342,780 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Loxo Oncol | JAYPIRCA | pirtobrutinib | TABLET;ORAL | 216059-001 | Jan 27, 2023 | RX | Yes | No | 10,342,780 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Loxo Oncol Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 202107472 | ⤷ Start Trial |
| Canada | 3224949 | ⤷ Start Trial |
| China | 117285467 | ⤷ Start Trial |
| Netherlands | 301262 | ⤷ Start Trial |
| Singapore | 11201805044W | ⤷ Start Trial |
| Lithuania | 3390395 | ⤷ Start Trial |
| Norway | 2024008 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Loxo Oncol Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3390395 | 301262 | Netherlands | ⤷ Start Trial | PRODUCT NAME: PIRTOBRUTINIB; REGISTRATION NO/DATE: EU/1/23/1738 20231031 |
| 3390395 | 2024C/506 | Belgium | ⤷ Start Trial | PRODUCT NAME: PIRTOBRUTINIB; AUTHORISATION NUMBER AND DATE: EU/1/23/1738 20231031 |
| 3390395 | C202430005 | Spain | ⤷ Start Trial | PRODUCT NAME: PIRTOBRUTINIB; NATIONAL AUTHORISATION NUMBER: EU/1/23/1738; DATE OF AUTHORISATION: 20231030; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1738; DATE OF FIRST AUTHORISATION IN EEA: 20231030 |
| 3390395 | C20240004 | Finland | ⤷ Start Trial | |
| 3390395 | C03390395/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: PIRTOBRUTINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68733 30.11.2023 |
| 3390395 | 4/2024 | Austria | ⤷ Start Trial | PRODUCT NAME: PIRTOBRUTINIB; REGISTRATION NO/DATE: EU/1/23/1738 (MITTEILUNG) 20231031 |
| 3390395 | CA 2024 00006 | Denmark | ⤷ Start Trial | PRODUCT NAME: PIRTOBRUTINIB; REG. NO/DATE: EU/1/23/1738 20231031 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
